Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Highlights•Tumor immune escape compromises the efficacy of cancer immunotherapy.•Loss
of MHC class I expression is a frequent event in cancer cells.•Three tumor phenotypes …

Tumours can escape T‐cell responses by losing major histocompatibility complex
(MHC)/human leucocyte antigen (HLA) class I molecules. In the early stages of cancer …

T cell-mediated immune therapies have emerged as a promising treatment modality in
different malignancies including colorectal cancer (CRC). However, only a fraction of …

The ability of cancer cells to escape from the natural or immunotherapy‐induced antitumor
immune response is often associated with alterations in the tumor cell surface expression of …

Most tumor cells derive from MHC-I-positive normal counterparts and remain positive at
early stages of tumor development. T lymphocytes can infiltrate tumor tissue, recognize and …

An intact immune system is essential to prevent the development and progression of
neoplastic cells in a process termed immune surveillance. During this process the innate …

Recent studies have suggested that a natural function of the immune system is to respond
and destroy aberrant, dysfunctional cells by a process called immunosurveillance. These …

MHC/HLA class I loss in cancer is one of the main mechanisms of tumor immune escape
from T-cell recognition and destruction. Tumor infiltration by T lymphocytes (TILs) and by …